HeRO™
Receives
FDA Clearance
Medical
Predictive Science Corporation
Announces
FDA Clearance of HeRO System for
Detecting Transient Decelerations and Reduced Baseline Heart Rate
Variability
May
12, 2003: Medical
Predictive Science Corporation (MPSC) has announced that it has received
FDA 510(k) clearance of
its HeRO™ (Heart
Rate Observation System) system that provides an
automated, non-invasive method to detect transient decelerations and
reduced baseline heart rate variability (HRV).
"HeRO
technology was developed and patented by researchers at the University
of Virginia, and this event marks the culmination of over a decade of
clinical research, " stated Greg Menke, MPSC Managing Director,
“and we're excited about the impact that HeRO will have in the future
of neonatal care."
Used
in neonatal intensive care units, HeRO, continuously acquires, records,
measures and analyzes HRV and provides a real-time display of this
information. HeRO represents
the leading edge of what MPSC sees as a family of innovative diagnostic
tools. Future products
under investigation include advanced fetal monitors and hypoglycemia
early warning monitors for diabetics.
#
# #
Medical
Predictive Science Corporation (http://www.mpsc.biz)
is engaged in the development of computational diagnostic and bio-informatic
technologies for the healthcare industry.
MPSC is committed to saving lives and reducing healthcare
expenditures through the development of effective clinical diagnostic
and decision support tools. These
products use computational diagnostic methods to make the early
diagnosis of clinical illness through continuous, non-invasive patient
monitoring, and to provide diagnostic information as well as decision
support to the physician.
HeRO is a trademark
of Medical
Predictive Science Corporation.
|
